AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive (COPD)
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 218
- Registration Number
- NCT05915182
- Locations
- 🇬🇷
Research Site, Thessaloniki, Greece
HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 774
- Registration Number
- NCT05905939
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)
Completed
- Conditions
- COPD
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 708
- Registration Number
- NCT05903989
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05898412
- Locations
- 🇳🇱
Research Site, Amsterdam, Netherlands
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
Active, not recruiting
- Conditions
- Neurofibroma
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT05891847
- Locations
- 🇷🇺
Research Site, Saint-Petersburg, Russian Federation
HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia
Completed
- Conditions
- Adenocarcinoma
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 204
- Registration Number
- NCT05892926
- Locations
- 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05888207
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
Recruiting
- Conditions
- Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT05887011
- Locations
- 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Phase 3
Active, not recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 111
- Registration Number
- NCT05883644
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaColorectal CarcinomaBreast CancerPancreatic AdenocarcinomaOther Solid TumorsNon-small Cell Lung CancerOvarian Cancer
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 162
- Registration Number
- NCT05877599
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Hoag Medical Group, Newport Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath